Cargando…
Annual Bleeding Rates: Pitfalls of Clinical Trial Outcomes in Hemophilia Patients
Emerging treatment options for hemophilia, including gene therapy, modified factor products, antibody‐based products, and other nonreplacement therapies, are in development or on their way to marketing authorization. For proof of efficacy, annual bleeding rates (ABRs) have become an increasingly imp...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719362/ https://www.ncbi.nlm.nih.gov/pubmed/32472976 http://dx.doi.org/10.1111/cts.12794 |